STAT

Sam Isaly leaves OrbiMed months after harassment allegations

More than four months after promising to resign, Sam Isaly has stepped down from biotech’s most powerful hedge fund in the wake of allegations of rampant sexual harassment.

More than four months after from biotech’s most powerful hedge fund, Sam Isaly has stepped down from in the wake of allegations of rampant sexual harassment.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Eli Lilly’s Anti-vanity Ad Campaign For Oscars
Eli Lilly will be unveiling a new campaign during this weekend’s Oscar awards event, with a clear message: These drugs aren’t meant to be used for cosmetic reasons. "It matters…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Congress Punts PBM Reform, Another Obesity Drug And More
BioMarin Pharmaceutical received a subpoena from the U.S. Department of Justice seeking information about the sponsored testing programs.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Weight Loss Drugs, A Cell Therapy For Melanoma, And More
China has more obese people than anywhere else in the world, and they are increasingly turning to weight loss drugs, fueling a gray market.